Minitablets in Japan: no new dosage form, count or weight decides

Japan's Pharmaceuticals and Medical Devices Agency (PMDA) posted "Handling of minitablets and similar products as a dosage form" on November 5, 2026, as technical information on the Japanese Pharmacopoeia. Dated September 2026, it comes from the Committee on Preparations of the body that drafts the pharmacopoeia. Minitablets and granular tablets are small shaped solids given several at a time, developed for patients who have trouble swallowing, children and the elderly among them, and for patients needing dose adjustment. It is not a notification or a guideline: the committee sets out its thinking at this point in time. For anyone filing or marketing one in Japan, the point that matters is that dispensing by number of units or by weighed amount decides whether the product is managed as tablets or granules, and sets the unit for evaluating uniformity of dosage units.

No separate dosage form in the pharmacopoeia, for now

The committee considers the need for a new dosage form, separate from tablets and granules in the monographs for preparations, to be low at present. Route and form of administration make a clear boundary with existing preparations hard to draw, so these products sit on an extension of tablets and granules with no essential technical novelty. With preparations of widely varying size in development, writing a scope and quality requirements for a new category also risks unnecessary restrictions, and a survey outside Japan confirmed handling within existing dosage forms.

The pharmacopoeia is a legal standard, not a reference work, as the comparison with USP and Ph. Eur. sets out, and its General Rules for Preparations is where dosage forms are defined.

Count or weighed amount sets the class, not the test the product passes

The starting point the committee chose is the operation performed at dispensing or when the medicine is taken, because it connects directly to the dose the patient receives. The committee considers it appropriate to manage products dispensed or taken by a specified number of units as tablets, and products dispensed by a specified weighed amount as granules. Which of the two a product uses is chosen on its characteristics and how it is used.

That is not the starting point industry asked for. The request letter of August 18, 2025 proposed tying classification to the quality control method: an individual minitablet conforming to the uniformity of dosage units test for tablets would be classified as tablets, and a one-dose package conforming to the test for granules as granules. It came from pediatric formulation groups at the Academy of Pharmaceutical Science and Technology Japan, JPMA and the Japan Generic Medicines Association.

A set of tablets can be the uniformity unit when the approved minimum dose needs several

For products dispensed by number of units, the unit for evaluating uniformity of dosage units is in principle the individual tablet. Where the approval states a minimum dose made up of several tablets, that set can be the unit for evaluating uniformity of dosage units and similar attributes. For products dispensed by weighed amount, the position follows granules generally: the test applies to single-dose packages and not to products supplied otherwise.

Content variation at low doses sits behind this: uneven distribution of the active ingredient and mass variation between shaped solids can make the content per dosing unit vary, and holding that down matters for efficacy and safety in pediatric patients. The committee names two technical difficulties: smaller shaped solids can make the specified values for uniformity of dosage units hard to meet, and dissolution can be hard to evaluate at the minimum dosing unit.

What to check for a minitablet you take into Japan

Read your own dosage and administration text first, since the classification turns on it: is the dose specified as a number of units or as a weighed amount, and is the approval's minimum dose one tablet or several? Those two answers fix the unit for uniformity of dosage units, and the rationale for using a set rather than the single tablet is worth writing down early.

On naming, the committee holds that the pharmacopoeia expresses no view on whether a product's brand name is acceptable. It does consider that descriptions using the names "granular tablet" and "minitablet" have a certain validity for conveying a product's features and use. The request letter had asked for permission to attach the granular tablet name to products classifiable as tablets, plus a notification on how such names are handled. The committee did not take that step.

If minitablets come into wide use and knowledge accumulates among developers, healthcare professionals and the authorities, the committee writes, the dosage form handling and control method may need a fresh arrangement.